Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels - PubMed (original) (raw)

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels

Ren-Qiang Liu et al. J Integr Agric. 2017 Oct.

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV), a member of the Coronaviridae family, is the causative pathogen for MERS that is characterized by high fever, pneumonia, acute respiratory distress syndrome (ARDS), as well as extrapulmonary manifestations. Currently, there are no approved treatment regimens or vaccines for MERS. Here, we generated recombinant nonvirulent Newcastle disease virus (NDV) LaSota strain expressing MERS-CoV S protein (designated as rLa-MERS-S), and evaluated its immunogenicity in mice and Bactrian camels. The results revealed that rLa-MERS-S showed similar growth properties to those of LaSota in embryonated chicken eggs, while animal immunization studies showed that rLa-MERS-S induced MERS-CoV neutralizing antibodies in mice and camels. Our findings suggest that recombinant rLa-MERS-S may be a potential MERS-CoV veterinary vaccine candidate for camels and other animals affected by MERS.

Keywords: MERS-CoV; Newcastle disease virus; camels; neutralizing antibodies.

PubMed Disclaimer

Cited by

Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review).
Babaeimarzangou SS, Zaker H, Soleimannezhadbari E, Gamchi NS, Kazeminia M, Tarighi S, Seyedian H, Tsatsakis A, Spandidos DA, Margina D. Babaeimarzangou SS, et al. Exp Ther Med. 2022 Nov 30;25(1):42. doi: 10.3892/etm.2022.11741. eCollection 2023 Jan. Exp Ther Med. 2022. PMID: 36569444 Free PMC article. Review.
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels.
Alharbi NK, Aljamaan F, Aljami HA, Alenazi MW, Albalawi H, Almasoud A, Alharthi FJ, Azhar EI, Barhoumi T, Bosaeed M, Gilbert SC, Hashem AM. Alharbi NK, et al. Vaccines (Basel). 2022 Aug 17;10(8):1330. doi: 10.3390/vaccines10081330. Vaccines (Basel). 2022. PMID: 36016218 Free PMC article.
Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease.
Díaz MF, Calderón K, Rojas-Neyra A, Vakharia VN, Choque-Guevara R, Montalvan-Avalos A, Poma-Acevedo A, Rios-Matos D, Agurto-Arteaga A, Cauti-Mendoza MG, Perez-Martinez N, Isasi-Rivas G, Tataje-Lavanda L, Sernaque-Aguilar Y, Ygnacio F, Criollo-Orozco M, Huaccachi-Gonzalez E, Delgado-Ccancce E, Villanueva-Pérez D, Montesinos-Millán R, Gutiérrez-Manchay K, Pauyac-Antezana K, Ramirez-Ortiz I, Quiñones-Garcia S, Cauna-Orocollo Y, Vallejos-Sánchez K, Rios-Angulo A, Núñez-Fernández D, Salguedo-Bohorquez MI, Ticona J, Fernández-Sánchez M, Icochea E, Guevara-Sarmiento LA, Zimic M; COVID-19 Working Group in Perú. Díaz MF, et al. Sci Rep. 2022 Jun 20;12(1):10359. doi: 10.1038/s41598-022-13560-z. Sci Rep. 2022. PMID: 35725862 Free PMC article.
An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice.
Zhao Y, Zhao L, Li Y, Liu Q, Deng L, Lu Y, Zhang X, Li S, Ge J, Bu Z, Ping J. Zhao Y, et al. Vet Microbiol. 2022 Aug;271:109491. doi: 10.1016/j.vetmic.2022.109491. Epub 2022 Jun 9. Vet Microbiol. 2022. PMID: 35714529 Free PMC article.
Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.
Fulber JPC, Kamen AA. Fulber JPC, et al. Viruses. 2022 May 6;14(5):975. doi: 10.3390/v14050975. Viruses. 2022. PMID: 35632717 Free PMC article. Review.

References

1. OIE (World Organisation for Animal Health) OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Office International des Epizooties; Paris: 2004.
1. Annan A, Baldwin H J, Corman V M, Klose S M, Owusu M, Nkrumah E E, Badu E K, Anti P, Agbenyega O, Meyer B, Oppong S, Sarkodie Y A, Kalko E K, Lina P H, Godlevska E V, Reusken C, Seebens A, Gloza-Rausch F, Vallo P, Tschapka M. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerging Infectious Diseases. 2013;19:456–459. - PMC - PubMed
1. Azhar E I, El-Kafrawy S A, Farraj S A, Hassan A M, Al-Saeed M S, Hashem A M, Madani T A. Evidence for camel-to-human transmission of MERS coronavirus. The New England Journal of Medicine. 2014;370:2499–2505. - PubMed
1. Belouzard S, Millet J K, Licitra B N, Whittaker G R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4:1011–1033. - PMC - PubMed
1. Bukreyev A, Collins P L. Newcastle disease virus as a vaccine vector for humans. Current Opinion in Molecular Therapeutics. 2008;10:46–55. - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels - PubMed (original) (raw)